<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-21</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-21</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>40</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Embryonic stem cell factors DPPA2/4åœ¨éå°ç»†èƒè‚ºç™Œä¸­æ¿€æ´»H3K4me3-H2AK119ubæŸ“è‰²è´¨åŒºåŸŸï¼Œæ˜¯è‚¿ç˜¤å‘ç”Ÿçš„é‡è¦æœºåˆ¶ã€‚TAS1440ä½œä¸ºLSD1æŠ‘åˆ¶å‰‚ï¼Œé€šè¿‡ç ´åINSM1-LSD1å¤åˆç‰©ï¼Œè½¬å½•é‡ç¼–ç¨‹æ¿€æ´»è‚¿ç˜¤æŠ‘åˆ¶é€šè·¯ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«é€ƒé€¸ï¼šCGRPä¿¡å·é€šè·¯åœ¨å£è…”é³çŠ¶ç»†èƒç™Œä¸­è¿æ¥è‚¿ç˜¤ç›¸å…³ç–¼ç—›ä¸å…ç–«é€ƒé€¸ï¼›IL11åœ¨è‚ç»†èƒç™Œä¸­ä¿ƒè¿›å…ç–«é€ƒé€¸ã€‚<br />
- ç™Œç—‡æ²»ç–—ä¸è€è¯æœºåˆ¶ï¼šADAM10æŠ‘åˆ¶åœ¨ç»“ç›´è‚ ç™Œä¸­çš„è½¬å½•æ•ˆåº”ï¼›Propranololé€šè¿‡ä¸Šè°ƒCDK11é€†è½¬é»‘è‰²ç´ ç˜¤çš„vemurafenibè€è¯ã€‚<br />
- è¡¨è§‚é—ä¼ è°ƒæ§ä¸è‚¿ç˜¤ï¼šDPPA2/4åœ¨éå°ç»†èƒè‚ºç™Œä¸­è°ƒæ§æŸ“è‰²è´¨çŠ¶æ€ï¼›LSD1æŠ‘åˆ¶å‰‚TAS1440åœ¨ç¥ç»å†…åˆ†æ³Œå°ç»†èƒè‚ºç™Œä¸­çš„ä½œç”¨ã€‚<br />
- ä»£è°¢é‡ç¼–ç¨‹ä¸ç–¾ç—…ï¼šNFATc3/ASK1åœ¨è„‚è‚ªæ€§è‚ç‚ä¸­çš„ä½œç”¨ï¼›ä¹³é…¸ä»‹å¯¼çš„èƒ†å›ºé†‡æ‘„å–ä¿ƒè¿›è‚ç™Œè¿›å±•ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å¤šç»„å­¦è”åˆåˆ†æï¼ˆMulti-omic profilingï¼‰æ­ç¤ºé¼»æ—çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒã€‚<br />
- å•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰åˆ†æè‚ºè½¬ç§»å¾®ç¯å¢ƒåŠè‚¿ç˜¤å†…ç”¨æº¶ç˜¤è…ºç—…æ¯’æ²»ç–—åçš„GBMã€‚</p>
<h3>ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
freeCount R Shiny åº”ç”¨é€šè¿‡ Posit Connect Cloud ç®€åŒ–äº†åœ¨çº¿ä½¿ç”¨æµç¨‹ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åœ¨çº¿éƒ¨ç½²å’Œä½¿ç”¨ R Shiny ç”Ÿç‰©ä¿¡æ¯å­¦åº”ç”¨ã€‚<br />
- ç®€åŒ–æ•°æ®åº”ç”¨çš„éƒ¨ç½²å’Œåˆ†äº«ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- Posit Connect Cloud æä¾›ä¾¿æ·çš„åœ¨çº¿è®¿é—®å’Œéƒ¨ç½²å¹³å°ã€‚<br />
- freeCount R Shiny åº”ç”¨ä½œä¸ºä¸€ç§æ˜“äºä½¿ç”¨çš„ç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
*   ç§‘å­¦å®¶å¼€å‘å‡ºDBiTplusæŠ€æœ¯ï¼Œé¦–æ¬¡å®ç°åœ¨åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸Šæ•´åˆæˆåƒå’Œæµ‹åºçš„ç©ºé—´ç»„å­¦åˆ†æï¼Œå®ç°åŸºå› ä¸è›‹ç™½è´¨ç›¸äº’ä½œç”¨çš„å•ç»†èƒç©ºé—´è§£æã€‚<br />
*   ç ”ç©¶æ­ç¤ºä¹³è…ºç™Œèƒ½è¿…é€Ÿæ‰°ä¹±å¤§è„‘æ˜¼å¤œèŠ‚å¾‹ï¼Œå¼•å‘ç„¦è™‘å’Œå¤±çœ ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>å…ç–«å­¦ä¸ç²¾å‡†åŒ»ç–—</strong>ï¼šImmunaié€šè¿‡å•ç»†èƒRNAæµ‹åºç»˜åˆ¶é«˜åˆ†è¾¨ç‡å…ç–«å›¾è°±ï¼Œèµ‹èƒ½è‡ªèº«å…ç–«ã€ç™Œç—‡å…ç–«ç–—æ³•å’Œç»†èƒç–—æ³•ç ”ç©¶ã€‚<br />
*   <strong>ç™Œç—‡ç ”ç©¶ä¸æ²»ç–—</strong>ï¼š<br />
    *   åˆ©ç”¨å°é¼ æ¨¡å‹ç ”ç©¶ç™Œç—‡å¯¹å¤§è„‘åŠŸèƒ½ï¼ˆå¦‚æ˜¼å¤œèŠ‚å¾‹ï¼‰çš„å½±å“ã€‚<br />
    *   çªç ´æ€§å‘ç°ä»å¹²ç»†èƒåŸ¹å…»è¾…åŠ©Tç»†èƒï¼Œä¸ºå…ç–«ç–—æ³•æä¾›æ–°é€”å¾„ã€‚<br />
    *   åˆæ­¥è¯æ®è¡¨æ˜å¸ƒæ´›èŠ¬å¯èƒ½é™ä½æŸäº›ç™Œç—‡ï¼ˆå¦‚å­å®«å†…è†œç™Œã€ç»“è‚ ç™Œï¼‰çš„é£é™©ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>DBiTplus</strong>ï¼šé›†æˆæˆåƒå’Œæµ‹åºçš„ç©ºé—´ç»„å­¦æ–¹æ³•ï¼Œåœ¨åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸Šå®ç°å¤šæ¨¡æ€ä¿¡æ¯å…³è”ã€‚<br />
*   <strong>TSniffer</strong>ï¼šæ— åå€šåœ°è¯†åˆ«RNAç¼–è¾‘ä½ç‚¹å¹¶é‡åŒ–ç¼–è¾‘æ´»æ€§ï¼ŒåŠ©åŠ›RNAç¼–è¾‘ç ”ç©¶ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (33æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE315799 CGRPä¿¡å·é€šè·¯å°†è‚¿ç˜¤ç›¸å…³ç–¼ç—›ä¸å£è…”é³çŠ¶ç»†èƒç™Œçš„å…ç–«é€ƒé€¸è”ç³»èµ·æ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Amin Reza Nikpoor ; Maryam Ahmadi ; Sebastien Talbot ; Nicole ScheffSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPeripheral sensory nerves are thought to contribute to solid tumor growth, particularly in oral squamous cell carcinoma (OSCC); however, the link between pain and immunosuppression remains unresolved. Here, using a prospective observational study, we demonstrate an inverse relationship between OSCC-induced pain mediated by calcitonin gene-related peptide (CGRP)-expressing nerves and tumor-associated immunity. Bulk RNA sequencing of tumor-innervating sensory neurons from mice revealed differential regulation of genes associated with excitability, neurotransmission, and axonal sprouting. Using a gain-of-function approach with persistent stimulation of peptidergic afferents, we show that sensory neurons promote oral tongue tumor growth and limit the activation of effective anti-tumor immune responses via efferent CGRP release. Conversely, loss-of-function approachesâ€”including local ablation of nociceptive nerves and systemic CGRP receptor antagonismâ€”slowed tumor growth and improved anti-tumor immunity. Targeting CGRP may therefore represent a therapeutic strategy in OSCC to reduce pain and improve treatment response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315799" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE291434 BMDM-Tç»†èƒå…±åŸ¹å…»ç³»ç»Ÿåœ¨æœ‰æˆ–æ— è‚¿ç˜¤æŠ—åŸå’ŒIL-1Î²æˆ–IL-18å­˜åœ¨ä¸‹çš„æ‰¹é‡RNAæµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€antigenã€RNAseq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ziqi Zhang ; Lei ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo investigate the transcriptome changes of BMDM-T cell co-culture system, spleen lyphocytes were cultured with WT or Tmem175-/- BMDMs in 1640 supplied with FBS, m-CSF, and IL-2 for 48 hours. Tumor antigens, IL-1beta (500 pg/ml), or IL-18 (500 pg/ml) were added during the co-culture period. At the end of the culture, cells were harvested for RNA seq.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291434" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE278149 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€tumor microenvironment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Methylation profiling by genome tiling array ; Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278149" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE314637 RNA-seqåˆ†æå·¨å™¬ç»†èƒNFATc3æˆ–ASK1å¯¹ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³è„‚è‚ªæ€§è‚ç‚çš„å½±å“</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmacrophageã€metabolicã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Si-Jia LiangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo explore the roles of macrophage NFATc3 and ASK1 in metabolic dysfunction-associated steatohepatitis, we generated macrophage-specific Nfatc3 knockout mice (Nfatc3-MKO), macrophage-specific Ask1 knockout mice (Ask1-MKO),macrophage-specific double knockout (MDKO) mice, macrophage-specific Nfatc3 knockin mice (Nfatc3-MKI), and macrophage-specific Ask1 knockin mice (Ask1-MKI). Lyz2-Cre mice were used as control. Eight-week-old male Lyz2-Cre, Nfatc3-MKO, Ask1-MKO, and MDKO mice were treated with methionine- and choline-deficient (MCD) diet for 4 weeks. Subsequently, mouse liver tissues were isolated and subjected to RNA sequencing analysis. In addition, mouse bone marrow-derived macrophages (BMDMs) were isolated from Lyz2-Cre, Nfatc3-MKI, and Ask1-MKI mice and were also subjected to RNA sequencing analysis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314637" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE311919 ä»£è°¢é‡ç¼–ç¨‹è°ƒæ§æ–‘é©¬é±¼å°¾é³å†ç”Ÿè¿‡ç¨‹ä¸­çš„ç»„è›‹ç™½ä¹³é…¸åŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jorge Borbinha ; Raquel LourenÃ§o ; Ana S BrandÃ£o ; Daniel Ribeiro ; Ana Carvalho ; Rune Matthiesen ; AntÃ³nio JacintoSeries Type : Expression profiling by high throughput sequencingOrganism : Danio rerioTissue regeneration relies on precise molecular mechanisms controlling cell fate transitions, with cell metabolism emerging as a key regulator. Lactate-derived histone lactylation has recently been identified as an important epigenetic modification involved in the regulation of gene expression across various biological processes. In this study, we report an increase in global histone lactylation and H3K18Lac levels in the mesenchyme and osteoblasts of the zebrafish caudal fin, during the early stages of regeneration. Our findings demonstrate that this epigenetic modification is functionally regulated by increased lactate levels, while inhibition of glycolysis and lactate production significantly reduces histone lactylation. These results suggest that metabolic reprogramming, in response to caudal fin injury, regulates histone lactylation, potentially modulating gene expression essential for cell plasticity and proliferation. This study expands our understanding of how metabolic-epigenetic interactions influence regenerative processes, providing valuable insights for the development of novel therapeutic strategies to enhance tissue repair.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311919" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE311253 RNA-seq åˆ†æ ADAM10 æŠ‘åˆ¶åœ¨ DLâ€‹â€‹D-1 å’Œ SW620 ç»“ç›´è‚ ç™Œç»†èƒç³»ä¸­çš„è¡¨è¾¾æƒ…å†µ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThis study examines the transcriptomic effects of ADAM10 inhibition in two human colorectal cancer cell lines, DLD-1 and SW620. Cells were treated with vehicle control or the conformation-specific ADAM10 monoclonal antibody 1H5 for 48 hours, followed by extraction of total RNA and paired-end RNA sequencing. The dataset enables comparative analysis of ADAM10-regulated pathways across different CRC genetic backgrounds, including alterations in Notch and EGFR signaling, metabolic gene programs, and other pathways associated with tumor progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311253" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE310170 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (RNA-seq)</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Janith A Seneviratne ; Melanie A Eckersley-MaslinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEmbryonic regulators are often re-expressed in cancers, however the functional and molecular significance of this is not always understood. The epigenetic priming factors Developmental Pluripotency Associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal in non-small cell lung cancer (NSCLC), DPPA2/4 co-expression is associated with poorly differentiated tumours and impaired patient outcomes. Biochemically, human DPPA2/4 multimerise for their protein stability and enhanced nucleosome binding activity. In NSCLC cells, DPPA2/4 bind CG-rich sequences including promoters of developmental, Wnt signaling and catabolic genes. Chromatin state modelling revealed DPPA2/4 preferentially bind active H3K4me3 and H3K27ac domains that were intriguingly also enriched for PRC1 and its product H2AK119ub, validated by H3K4me3-H2AK119ub sequential ChIP. Knockdown experiments revealed DPPA2/4 were required to maintain RING1B and H2AK119ub at these domains. Surprisingly, despite the presence of PRC2.1, these regions lacked any detectable H3K27me3, suggesting an uncoupling between the recruitment of PRC2 to chromatin and its catalytic product. When exogenously over-expressed in NSCLC cells where they are not normally present, DPPA2/4 bind to and promote active chromatin states, resulting in an increase in vivo xenograft tumour growth. Our results demonstrate how in NSCLC cells, DPPA2/4 act as molecular amplifiers of active and poised chromatin. Together, this highlights how aberrant re-activation of embryonic factors in cancers may take on new functions, promoting tumourigenesis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310170" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE310167 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (ChIP-seq)</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Janith A Seneviratne ; Melanie A Eckersley-MaslinSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensEmbryonic regulators are often re-expressed in cancers, however the functional and molecular significance of this is not always understood. The epigenetic priming factors Developmental Pluripotency Associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal in non-small cell lung cancer (NSCLC), DPPA2/4 co-expression is associated with poorly differentiated tumours and impaired patient outcomes. Biochemically, human DPPA2/4 multimerise for their protein stability and enhanced nucleosome binding activity. In NSCLC cells, DPPA2/4 bind CG-rich sequences including promoters of developmental, Wnt signaling and catabolic genes. Chromatin state modelling revealed DPPA2/4 preferentially bind active H3K4me3 and H3K27ac domains that were intriguingly also enriched for PRC1 and its product H2AK119ub, validated by H3K4me3-H2AK119ub sequential ChIP. Knockdown experiments revealed DPPA2/4 were required to maintain RING1B and H2AK119ub at these domains. Surprisingly, despite the presence of PRC2.1, these regions lacked any detectable H3K27me3, suggesting an uncoupling between the recruitment of PRC2 to chromatin and its catalytic product. When exogenously over-expressed in NSCLC cells where they are not normally present, DPPA2/4 bind to and promote active chromatin states, resulting in an increase in vivo xenograft tumour growth. Our results demonstrate how in NSCLC cells, DPPA2/4 act as molecular amplifiers of active and poised chromatin. Together, this highlights how aberrant re-activation of embryonic factors in cancers may take on new functions, promoting tumourigenesis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310167" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE310144 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (ATAC-seq)</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ATAC-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Janith A Seneviratne ; Melanie A Eckersley-MaslinSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensEmbryonic regulators are often re-expressed in cancers, however the functional and molecular significance of this is not always understood. The epigenetic priming factors Developmental Pluripotency Associated 2 and 4 (DPPA2/4) have crucial roles in early development and are implicated in cancer pathogenesis. We reveal in non-small cell lung cancer (NSCLC), DPPA2/4 co-expression is associated with poorly differentiated tumours and impaired patient outcomes. Biochemically, human DPPA2/4 multimerise for their protein stability and enhanced nucleosome binding activity. In NSCLC cells, DPPA2/4 bind CG-rich sequences including promoters of developmental, Wnt signaling and catabolic genes. Chromatin state modelling revealed DPPA2/4 preferentially bind active H3K4me3 and H3K27ac domains that were intriguingly also enriched for PRC1 and its product H2AK119ub, validated by H3K4me3-H2AK119ub sequential ChIP. Knockdown experiments revealed DPPA2/4 were required to maintain RING1B and H2AK119ub at these domains. Surprisingly, despite the presence of PRC2.1, these regions lacked any detectable H3K27me3, suggesting an uncoupling between the recruitment of PRC2 to chromatin and its catalytic product. When exogenously over-expressed in NSCLC cells where they are not normally present, DPPA2/4 bind to and promote active chromatin states, resulting in an increase in vivo xenograft tumour growth. Our results demonstrate how in NSCLC cells, DPPA2/4 act as molecular amplifiers of active and poised chromatin. Together, this highlights how aberrant re-activation of embryonic factors in cancers may take on new functions, promoting tumourigenesis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310144" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE272003 TAS1440ï¼Œä¸€ç§ LSD1 æŠ‘åˆ¶å‰‚ï¼Œé€šè¿‡è½¬å½•é‡ç¼–ç¨‹ç ´å INSM1-LSD1 å¤åˆç‰©ï¼Œä»è€Œæ¿€æ´»ç¥ç»å†…åˆ†æ³Œå°ç»†èƒè‚ºç™Œä¸­çš„è‚¿ç˜¤æŠ‘åˆ¶é€šè·¯ [ChIP-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Takumitsu Machida ; Yingbo Gong ; Sayaka Tsukioka ; Atsushi Onodera ; Akitoshi Nakayama ; Naoko Hashimoto ; Takahiro Fuchigami ; Satoshi Yamashita ; Tatsuya Suzuki ; Ryo Hatanaka ; Yasuo Kodama ; Shuichi Ohkubo ; Tomoaki TanakaSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensSmall cell lung cancer (SCLC) is characterized by aggressive progression and limited treatment options, necessitating novel therapeutic strategies. Lysine-specific histone demethylase 1A (LSD1), a key epigenetic enzyme essential for maintaining the neuroendocrine phenotype, represses NOTCH and TGF-Î² signaling. Reactivation of these pathways suppresses proliferation and induces differentiation, underscoring LSD1's potential as a therapeutic target. However, the molecular mechanisms underlying LSD1 inhibition and chemoresistance drivers remain poorly understood. Here, through structure-based engineering, we developed TAS1440, a potent histone H3-competitive LSD1 inhibitor designed to enhance specificity and reduce off-target effects. Unlike covalent inhibitors, which bind irreversibly to the FAD cofactor in LSD1, TAS1440 non-covalently targets the histone H3-binding pocket, improving safety and efficacy. TAS1440 demonstrated superior anti-proliferative activity in SCLC-A cells with high INSM1 and ASCL1 expression. In xenograft models, TAS1440 achieved over 70% tumor growth inhibition with minimal toxicity, highlighting its potential for SCLC. Mechanistically, integrated studies revealed that TAS1440 exerts dual mechanisms: direct inhibition of LSD1 enzymatic activity and disruption of LSD1-repressive complexes, thereby altering the histone modification landscape and activating transcription factors such as INSM1 and SMAD2. These actions coordinately reprogram tumor-suppressive pathways, including TGF-Î² and NOTCH signaling, positioning TAS1440 as an effective epigenetic therapy for SCLC. Importantly, Loss of LSD1 enzymatic activity and INSM1 knockout abrogated TAS1440â€™s effects, elucidating its mechanism of action and uncovering potential resistance pathways. These findings establish TAS1440 as a next-generation LSD1 inhibitor with dual actions on transcriptional regulation and epigenetic reprogramming. TAS1440 holds significant promise as a targeted therapy for SCLC, particularly for the SCLC-A subtype with high INSM1 expression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272003" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 23 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>åœ¨ Posit Connect Cloud ä¸Šä½¿ç”¨ freeCount è¿›è¡Œç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šbioinformatics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šThe easiest way to use the freeCount R Shiny applications online is through Posit Connect Cloud, which is an online platform that simplifies the deployment of data applications and documents. Continue reading: Bioinformatics Analysis on Posit Connect Cloud with freeCount<br />
- ğŸ”— <a href="https://www.r-bloggers.com/2026/01/bioinformatics-analysis-on-posit-connect-cloud-with-freecount/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (6æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨6æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>Immunaiå…¬å¸æ‰©å¤§å­¦æœ¯åˆä½œï¼Œåˆ©ç”¨å•ç»†èƒRNAæµ‹åºæŠ€æœ¯ç»˜åˆ¶å…ç–«ååº”å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€sequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šImmunai partners with leading academic centers to provide single-cell RNA sequencing and multi-omic data, building high-resolution immune maps across autoimmunity, cancer immunotherapy, and cell therapy...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/immunai-expands-academic-collaborations-with-single-cell-rna-sequencing-to-map-immune-responses/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>DBiTplusâ€”â€”åœ¨åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸Šæ•´åˆåŸºäºæˆåƒå’ŒåŸºäºæµ‹åºçš„ç©ºé—´ç»„å­¦å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€spatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šDBiTplus combines RNA sequencing and protein imaging on the same tissue section, enabling single-cell spatial maps that reveal how genes and proteins interact in health and disease...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/dbitplus-integration-of-imaging-based-and-sequencing-based-spatial-omics-mapping-on-the-same-tissue-section/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>TSnifferâ€”â€”å¯¹RNAæµ‹åºæ•°æ®ä¸­çš„RNAç¼–è¾‘ä½ç‚¹è¿›è¡Œæ— åå€šçš„ä»å¤´è¯†åˆ«å¹¶é‡åŒ–ç¼–è¾‘æ´»æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šTSniffer enables unbiased detection and quantification of RNA editing from RNA sequencing data, helping researchers study ADAR-driven transcriptome changes across...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/tsniffer-unbiased-de-novo-identification-of-rna-editing-sites-and-quantification-of-editing-activity-in-rna-seq-data/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç™Œç—‡å¦‚ä½•æ‰°ä¹±å¤§è„‘å¹¶å¼•å‘ç„¦è™‘å’Œå¤±çœ </strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have discovered that breast cancer can quietly throw the brainâ€™s internal clock off balanceâ€”almost immediately after cancer begins. In mice, tumors flattened the natural daily rhythm of stress hormones, disrupting the brain-body feedback loop that regulates stress, sleep, and immunity. Remarkably, when researchers restored the correct day-night rhythm in specific brain neurons, stress hormone cycles snapped back into place, immune cells flooded the tumors, and the cancers shrankâ€”without using any anti-cancer drugs.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260116035351.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>ç§‘å­¦å®¶æ”»å…‹ç™Œç—‡ç»†èƒç–—æ³•å‘å±•ä¸­çš„ä¸€ä¸ªé‡å¤§éšœç¢</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based cancer therapy. Helper T cells act as the immune systemâ€™s coordinators, helping other immune cells fight longer and harder. The team discovered how to precisely control a key signal that determines which type of T cell forms. This advance could lead to ready-made cell therapies that are cheaper, faster, and easier to access.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260120015654.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>ä¸€ç§å¸¸ç”¨æ­¢ç—›è¯å¯èƒ½æ­£åœ¨æ‚„ç„¶æ”¹å˜ç™Œç—‡é£é™©ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šIbuprofen may be doing more than easing aches and painsâ€”it could also help reduce the risk of some cancers. Studies have linked regular use to lower rates of endometrial and bowel cancer, likely because the drug dampens inflammation that fuels tumor growth. Researchers have even found it can interfere with genes cancer cells rely on to survive. Still, experts warn that long-term use carries risks and shouldnâ€™t replace proven prevention strategies.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260120000323.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>14</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>7</td>
</tr>
<tr>
<td>tumor</td>
<td>5</td>
</tr>
<tr>
<td>immune</td>
<td>4</td>
</tr>
<tr>
<td>sequencing</td>
<td>3</td>
</tr>
<tr>
<td>carcinoma</td>
<td>3</td>
</tr>
<tr>
<td>metabolic</td>
<td>3</td>
</tr>
<tr>
<td>macrophage</td>
<td>2</td>
</tr>
<tr>
<td>RNAseq</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>spatial</td>
<td>1</td>
</tr>
<tr>
<td>single-cell</td>
<td>1</td>
</tr>
<tr>
<td>resistance</td>
<td>1</td>
</tr>
<tr>
<td>histone</td>
<td>1</td>
</tr>
<tr>
<td>antigen</td>
<td>1</td>
</tr>
<tr>
<td>scRNA</td>
<td>1</td>
</tr>
<tr>
<td>antibody</td>
<td>1</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>1</td>
</tr>
<tr>
<td>bioinformatics</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (23æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272002" target="_blank" rel="noopener noreferrer">GSE272002 TAS1440ï¼Œä¸€ç§ LSD1 æŠ‘åˆ¶å‰‚ï¼Œé€šè¿‡è½¬å½•é‡ç¼–ç¨‹ç ´å INSM1-LSD1 å¤åˆç‰©ï¼Œä»è€Œæ¿€æ´»ç¥ç»å†…åˆ†æ³Œå°ç»†èƒè‚ºç™Œä¸­çš„è‚¿ç˜¤æŠ‘åˆ¶é€šè·¯ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223320" target="_blank" rel="noopener noreferrer">GSE223320 IL11 åœ¨ä¾µè¢­æ€§è‚ç»†èƒç™Œä¸­ç»„ç»‡å…·æœ‰å…ç–«é€ƒé€¸èƒ½åŠ›çš„å·¨æ¢ç»“æ„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316499" target="_blank" rel="noopener noreferrer">GSE316499 ç ”ç©¶å‘ç°ï¼Œæ™®è˜æ´›å°”é€šè¿‡ä¸Šè°ƒ CDK11 å¹¶è¯±å¯¼ç»†èƒå‘¨æœŸé˜»æ»ï¼Œå…‹æœé»‘è‰²ç´ ç˜¤å¯¹ç»´è«éå°¼çš„è€è¯æ€§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314097" target="_blank" rel="noopener noreferrer">GSE314097 å…šå‚å¤šç³–é€šè¿‡å·¨å™¬ç»†èƒé»é™„å’Œé’™ä¿¡å·ä¼ å¯¼å‡è½»å¸ƒé²æ°èŒå¤–è†œè›‹ç™½19è¯±å¯¼çš„å­å®«æŸä¼¤</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291346" target="_blank" rel="noopener noreferrer">GSE291346 å•ç»†èƒ RNA æµ‹åºåˆ†æ Tmem175 KO å’Œ WT å°é¼ è‚ºè½¬ç§»å¾®ç¯å¢ƒã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273303" target="_blank" rel="noopener noreferrer">GSE273303 ä½¿ç”¨ Î±-HER1 æŠ—ä½“è¿›è¡Œ HER1 å®šä½çš„ Cut&amp;Tag-seq åˆ†æï¼Œä»¥åŠä½¿ç”¨ Î±-H3K9me2 æŠ—ä½“è¿›è¡Œ WT å’Œ her1 çš„ Cut&amp;Tag-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273302" target="_blank" rel="noopener noreferrer">GSE273302 é‡ç”Ÿå‹å’Œ her1 æ°´ç¨» RNA æµ‹åºæ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316731" target="_blank" rel="noopener noreferrer">GSE316731 å†…çš®ç»†èƒç‰¹å¼‚æ€§NOX1æ¿€æ´»é€šè¿‡éª¨éª¼è‚Œçº¿ç²’ä½“åŠŸèƒ½éšœç¢é©±åŠ¨è‚¥èƒ–å’Œä»£è°¢ç»¼åˆå¾ï¼Œå¹¶å…·æœ‰æ–°çš„é—ä¼ ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316686" target="_blank" rel="noopener noreferrer">GSE316686 ç”¨agrinæˆ–MuSKæŠ—ä½“å¤„ç†çš„C2C12è‚Œç®¡çš„æ€»RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316557" target="_blank" rel="noopener noreferrer">GSE316557 ä¹³é…¸ä»‹å¯¼çš„èƒ†å›ºé†‡æ‘„å–é€šè¿‡ SCARB1-è‡ªå™¬è½´ä¿ƒè¿›è‚ç™Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316433" target="_blank" rel="noopener noreferrer">GSE316433 ç ”ç©¶å‘ç°ï¼Œå›´æ‰‹æœ¯æœŸåº”ç”¨å²©è—»èšç³–ä¼šè¯±å‘å…ç–«æŠ‘åˆ¶å˜åŒ–ï¼Œå¯¼è‡´æœ¯åç¥ç»è®¤çŸ¥åŠŸèƒ½æ¢å¤æœªè§è·ç›Šã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316327" target="_blank" rel="noopener noreferrer">GSE316327 HP1Î± ç¼ºå¤±å’Œ TGFÎ² æ¿€æ´»å¯¹ 3D åŸºå› ç»„ç»„ç»‡å…·æœ‰æ‹®æŠ—ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316315" target="_blank" rel="noopener noreferrer">GSE316315 æº¶ç˜¤è…ºç—…æ¯’æ²»ç–—ååŸä½èƒ¶è´¨æ¯ç»†èƒç˜¤çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314638" target="_blank" rel="noopener noreferrer">GSE314638 å°é¼ éª¨é«“æ¥æºå·¨å™¬ç»†èƒä¸­ NFATc3 è¿‡è¡¨è¾¾å¼•èµ·çš„æŸ“è‰²è´¨çŠ¶æ€å˜åŒ–çš„å…¨åŸºå› ç»„å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310173" target="_blank" rel="noopener noreferrer">GSE310173 èƒšèƒå¹²ç»†èƒå› å­DPPA2/4æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­æ´»æ€§H3K4me3-H2AK119ubæŸ“è‰²è´¨ç»“æ„åŸŸ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310171" target="_blank" rel="noopener noreferrer">GSE310171 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (reChIP-seq)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310165" target="_blank" rel="noopener noreferrer">GSE310165 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (ChIPRx-seq)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310161" target="_blank" rel="noopener noreferrer">GSE310161 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (CUT&amp;Run)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310160" target="_blank" rel="noopener noreferrer">GSE310160 èƒšèƒå¹²ç»†èƒå› å­ DPPA2/4 æ‰©å¢éå°ç»†èƒè‚ºç™Œä¸­çš„æ´»æ€§ H3K4me3-H2AK119ub æŸ“è‰²è´¨ç»“æ„åŸŸ (BS-seq)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302851" target="_blank" rel="noopener noreferrer">GSE302851 å¤šå‘æ€§éª¨é«“ç˜¤ä¸­çš„ç”²åŸºåŒ–å˜å¼‚æ€§å’ŒLINE-1æ¿€æ´»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285078" target="_blank" rel="noopener noreferrer">GSE285078 MRTFA-SRFé©±åŠ¨çš„åŸºå› è¡¨è¾¾é€šè¿‡æ§åˆ¶ç™Œç»†èƒä¸­ç»†èƒè´¨Ca2+å’ŒK+æ°´å¹³æ¥ä¿ƒè¿›ç»†èƒåˆšåº¦ II</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE241211" target="_blank" rel="noopener noreferrer">GSE241211 å°‘çªèƒ¶è´¨ç»†èƒå‰ä½“ç»†èƒé€šè¿‡BMP4é©±åŠ¨è·å¾—é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³çŠ¶æ€ï¼Œä»è€Œè°ƒèŠ‚å°èƒ¶è´¨ç»†èƒå‘ç¥ç»ä¿æŠ¤è¡¨å‹çš„è½¬å˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223356" target="_blank" rel="noopener noreferrer">GSE223356 TFRC-RNA ç›¸äº’ä½œç”¨ç»„æ­ç¤ºäº†äººç±»è‚¾å°ç®¡ç³»è†œç»†èƒä¸­ä¸ IgAN ç›¸å…³çš„åŸºå› çš„è¡¨è¾¾å’Œé€‰æ‹©æ€§å‰ªæ¥è°ƒæ§ [RNA-seq]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-20 21:40</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>